XPA基因A23G多态性与晚期非小细胞肺癌对铂类化疗的反应增强相关。

XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.

作者信息

Feng Jifeng, Sun Xinchen, Sun Ning, Qin Shukui, Li Fan, Cheng Hongyan, Chen Baoan, Cao Yuandong, Ma Jun, Cheng Lu, Lu Zuhong, Ji Jiazhong, Zhou Yingfeng

机构信息

Medical School, Southeast University, Nanjing, China.

出版信息

Acta Biochim Biophys Sin (Shanghai). 2009 May;41(5):429-35. doi: 10.1093/abbs/gmp027.

DOI:10.1093/abbs/gmp027

PMID:19430706

Abstract

DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the Aright curved arrow G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.

摘要

DNA修复能力（DRC）与癌细胞对铂类化疗的敏感性相关。我们假设，DNA修复基因XPA（着色性干皮病A组）和XPG（着色性干皮病G组）（ERCC5，切除修复交叉互补组5）中的基因多态性会导致个体间DNA修复效率的差异，这可能预测晚期非小细胞肺癌（NSCLC）患者对铂类药物的临床反应。在本研究中，我们发现XPA A23G多态性的A→G变化显著增加了对铂类化疗的反应。XPG His46His多态性与治疗反应降低相关，但无统计学意义。